Skip to content

Opinion

High Court should weigh in on health care reform

Whatever one thinks of the health care reform legislation, whose most far-reaching provisions are due to take effect in 2014, it should be welcome news that the Obama administration has asked the Supreme Court to consider the ongoing legal challenges to the law.

Cosby will bring change to CVS/pharmacy

or even distant — memory has a mass retailer tapped an outsider to head up its executive ranks. Yet that’s what is about to happen, on October 1, when Mark Cosby officially becomes president of the CVS/pharmacy unit of CVS Caremark. It is a daunting assignment. Depending on how one calculates

Giancamilli helps move community Rx ahead

When Andy Giancamilli steps down as chief executive officer of Katz Group Canada at the beginning of February, his move to an advisory role at the company will mark the end of a career in community pharmacy that exemplifies what the profession means for the people who practice it and the patients it

At ECRM, the focus shifts to Mitch Bowlus

The final goodbyes have been said, the last stories told. Only the memories of Charlie Bowlus linger, the memories of the personality behind the organization that charted new directions, opened new windows, explored new possibilities and developed new ways of doing business.

In uncertain times, pharmacy’s benefits stand out

As the leaders of community pharmacy gather in Boston for the National Association of Chain Drug Stores Pharmacy and Technology Conference, the profession continues to confront a number of unresolved issues that could have a direct bearing on its ability to provide accessible, affordable patient car

PBM merger reshapes playing field for Rx

a deal that, if it passes muster with government regulators, will combine two of the three largest pharmacy benefit management companies to create a dominant player in the sector — raises a host of challenges for community pharmacy operators and others involved

Merck Adherence Estimator demonstrates worth

The Adherence Estimator, a patient segmentation tool developed by researchers at Merck & Co. to help pharmacists and other health care professionals identify and assist individuals prone to medication nonadherence, has proved its worth in a variety of practice settings since its debut last year.